If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received from his parents’ neighbor might not have ...

A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the ...

Edwards Lifesciences Corp. raised its full-year 2026 guidance after seeing strong sales in the first quarter, particulalry ...

Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal ...

Anaptysbio Inc. announced in September of 2025 that it planned to separate its drug development business from the royalties it receives on Jemperli (dostarlimab) from GSK plc and imsidolimab from ...

Four months after receiving a complete response letter from the U.S. FDA for tolebrutinib to treat non-relapsing secondary ...

BioWorld tracked 209 clinical trial readouts across phases I through III in March 2026, up from 152 in February and 144 in ...

Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on investment (ROI). “I would say a lot of ...

An advantage of antibody-drug conjugates (ADCs) is that they allow targeted delivery of cytotoxic agents into tumors, thus improving the therapeutic index. Pfizer Inc. has developed a new ADC, ...

Jiangsu Carephar Pharmaceutical Co. Ltd. has patented angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.

Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed ...

Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the treatment of depression, bipolar disorder, ...